Catalyst
Slingshot members are tracking this event:
Discovery Labs has initiated its AEROSURF phase 2b clinical trial in premature infants 26 to 32 weeks gestational age receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS).
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| DSCO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 29, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aerosurf, Phase 2b, Trial, Rds
